IDiyas

For the Inventor, By the Inventor

Yongin-si, South Korea

Jeongmin Kim

USPTO Granted Patents = 10 


Average Co-Inventor Count = 10.7

ph-index = 2

Forward Citations = 33(Granted Patents)


Company Filing History:

goldMedal7 out of 260 
 
The Green Cross Corporation
 patents
silverMedal3 out of 8 
 
Gc Cell Corporation
 patents

Years Active: 2012-2025

Loading Chart...
Loading Chart...
10 patents (USPTO):
1. 12410261 - Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same (2025-09-09),
2. 11970547 - Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same (2024-04-30),
3. 11649294 - Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same (2023-05-16),
4. 8895558 - Arylpiperazine-containing pyrrole 3-carboxamide derivatives for treating depressive disorders (2014-11-25),
5. 8835436 - Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same (2014-09-16),
6. 8785453 - Arylpiperazine-containing purine derivatives and uses thereof (2014-07-22),
7. 8586550 - Thiazole derivatives as SGLT2 inhibitors and pharmaceutical composition comprising same (2013-11-19),
8. 8541380 - C-aryl glucoside SGLT2 inhibitors and pharmaceutical compositions comprising same (2013-09-24),
9. 8309584 - Sulfur containing pyrazole-heterocycle derivatives as cannabinoid CB1 receptor antagonists (2012-11-13),
10. 8178551 - Orally bioavailable prodrugs of (+)-3-hydroxymorphinan for Parkinson'S disease prevention or treatment (2012-05-15),

Title: The Innovative Contributions of Jeongmin Kim

Introduction

Jeongmin Kim is a prominent inventor based in Yongin-si, South Korea. He has made significant contributions to the field of biotechnology, particularly in cancer treatment. With a total of 10 patents to his name, Kim's work has the potential to impact the lives of many patients suffering from cancer.

Latest Patents

Among his latest patents is a novel anti-HER2 antibody or an antigen-binding fragment thereof. This invention is designed for the prevention or treatment of cancer, specifically targeting HER2, which is highly expressed in certain cancer cells, including breast and gastric cancer. The antibody binds to a unique epitope that differs from the one targeted by trastuzumab, offering a new avenue for therapeutic intervention.

Career Highlights

Jeongmin Kim has worked with notable companies in the biotechnology sector, including The Green Cross Corporation and GC Cell Corporation. His experience in these organizations has allowed him to develop and refine his innovative ideas, contributing to advancements in cancer therapies.

Collaborations

Throughout his career, Kim has collaborated with esteemed colleagues, including Jinhwa Lee and Suk Ho Lee. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise in the field of cancer research.

Conclusion

Jeongmin Kim's innovative work in developing anti-HER2 antibodies showcases his commitment to advancing cancer treatment. His contributions are paving the way for new therapeutic options that could significantly improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…